Form 4: 10x Genomics CEO Serge Saxonov Sells Shares to Cover Tax Obligations

10x Genomics CEO Serge Saxonov sold 4,877 shares of Class A Common Stock on May 22, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On May 22, 2024, Serge Saxonov, CEO of 10x Genomics, sold 4,877 shares of Class A Common Stock at a price of $24.3036 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Saxonov directly owns 889,641 shares of Class A Common Stock.
• Additionally, Saxonov indirectly owns shares through several trusts where he serves as trustee: Andromeda Trust (27 shares), Sirius Trust (870 shares), Y/S Descendants' Trust (213,250 shares), and Y/S Pot Trust (22,570 shares).

Sentiment

Score: 5

Explanation: This is a neutral event. The sale is related to tax obligations and doesn't necessarily indicate a change in the executive's confidence in the company.

Industry Context

This is a routine Form 4 filing, indicating insider transactions. It's common for executives to sell shares to cover tax obligations when restricted stock units vest. These transactions are publicly disclosed to maintain transparency and prevent insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The sale of shares to cover tax obligations is a common occurrence among executives receiving stock-based compensation.
• Companies like Illumina (ILMN) and Pacific Biosciences (PACB), which are competitors of 10x Genomics, also have executives who regularly file Form 4s for similar transactions.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price, but it's unlikely to be significant given the reason for the sale.

Key Dates